Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.36 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TK2 | O00142 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363668 | 0.88 | RNASE1 (0.45) | TK1RNASE1TK2PDE4D | |
| SCHEMBL6362720 | 0.81 | TOP2A (0.34) | TK1RNASE1TK2 | |
| SCHEMBL9396525 | 0.80 | RNASE1 (0.50) | TK1RNASE1ALDH1A1 | |
| SCHEMBL7975895 | 0.80 | RNASE1 (0.50) | TK1RNASE1TK2PDE4D | |
| SCHEMBL7788368 | 0.78 | PDE4D (0.45) | TK1RNASE1TK2PDE4DLMNA | |
| SCHEMBL6358756 | 0.76 | ALDH1A1 (0.34) | TK1ALDH1A1S1PR1S1PR5SMN1; SMN2 | |
| SCHEMBL9702755 | 0.73 | RNASE1 (0.48) | TK1RNASE1TK2PDE4D | |
| SCHEMBL9396372 | 0.73 | RNASE1 (0.42) | RNASE1 | |
| SCHEMBL31286197 | 0.73 | DHFR (0.39) | TK1RNASE1ALDH1A1TK2 | |
| SCHEMBL13415582 | 0.72 | CTSV (0.39) | TK1RNASE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900297-B1 | Amine-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1487855-A2 | METHOD OF USING MODIFIED OLIGONUCLEOTIDES FOR HEPATIC DELIVERY | ISIS Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040142899-A1 | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals | ISIS PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
| US-6753423-B1 | FOR PREFERENTIALLY MODULATED GENE EXPRESSION IN LIVER AND ASSOCIATED TISSUES | ISIS PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030191075-A1 | Method of using modified oligonucleotides for hepatic delivery | ISIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003072711-A2 | METHOD OF USING MODIFIED OLIGONUCLEOTIDES FOR HEPATIC DELIVERY | ISIS PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142899-A1 | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals | FABP1, RNASE1, RNGTT | TK1 38/4885RNASE1 2/4885ALDH1A1 1651/4885 |
| US-20030191075-A1 | Method of using modified oligonucleotides for hepatic delivery | FABP1, DCLRE1B, SLC10A1 | TK1 105/4885RNASE1 8/4885ALDH1A1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.